Mylan Issues Statement in Response to Abbott's Support for Perrigo Transaction

June 17, 2015

Mylan N.V. today issued a statement regarding Abbott Laboratories' announced intention to support Mylan's offer to acquire Perrigo Company plc.

PRESS RELEASE

HERTFORDSHIRE, England

and

PITTSBURGH

,

June 16, 2015

/PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement regarding Abbott Laboratories' (NYSE: ABT) announced intention to support Mylan's offer to acquire Perrigo Company plc (NYSE: PRGO; TASE) and vote in favor of this acquisition at Mylan's upcoming shareholder meeting.

Abbott

is currently Mylan's largest shareholder, owning 14.5% of Mylan's outstanding shares, and is an important long-term stakeholder of Mylan through various manufacturing partnerships.

Mylan Executive Chairman

Robert J. Coury

stated: "We are very pleased that, while

Abbott

is under no obligation to do so,

Abbott

has voluntarily chosen to express its support of Mylan, our strategic growth plan and stand-alone strategy, and our proposed combination with Perrigo. When we acquired

Abbott's

non-U.S. developed markets specialty and branded generics business earlier this year, we gained an important stakeholder in

Abbott

, which understands the powerful potential of our platform, and the critical importance of our scale and breadth across our distribution channels. We are grateful for

Abbott's

support of our long-term vision, which we firmly believe will continue to deliver strong near-term and long-term returns in this rapidly evolving industry and will promote the sustainable success of Mylan's business."